Shan Xin
Postdoctoral AssociateAbout
Research
Publications
2025
Spatially resolved C1QC+ macrophage-CD4+ T cell niche in colorectal cancer microenvironment: implications for immunotherapy response
Zhang H, Hong L, Dong Z, Xin S, Lin B, Cheng J, Tian W, Li B, Wang J, Liu X, Liu C, Jin Y, Feng Y, Su G, Sun X, Liu Q, Dai X, Gao Y, Tong Z, Liu L, Zhu X, Zheng Y, Zhao P, Guo T, Fang W, Bao X. Spatially resolved C1QC+ macrophage-CD4+ T cell niche in colorectal cancer microenvironment: implications for immunotherapy response. Cell Discovery 2025, 11: 60. PMID: 40593467, PMCID: PMC12219098, DOI: 10.1038/s41421-025-00811-2.Peer-Reviewed Original ResearchResident tissue macrophagesColorectal cancerImmunotherapy responseTumor microenvironmentNon-respondersCD4+ T cellsResistance to immunotherapyMetastatic colorectal cancerColorectal cancer microenvironmentMicrosatellite stabilityMHC-II expressionMicrosatellite instabilityT cell nicheCancer-associated fibroblastsMetastatic CRCImmunotherapy respondersT cellsImaging Mass CytometryAntigen presentationImmunotherapyCancer microenvironmentSingle-cell RNA sequencingMHC-IITissue macrophagesMass cytometrySpatial multi-omics profiling of breast cancer oligo-recurrent lung metastasis
Gao Y, Li B, Jin Y, Cheng J, Tian W, Ying L, Hong L, Xin S, Lin B, Liu C, Sun X, Zhang J, Zhang H, Xie J, Deng X, Dai X, Liu L, Zheng Y, Zhao P, Yu G, Fang W, Bao X. Spatial multi-omics profiling of breast cancer oligo-recurrent lung metastasis. Oncogene 2025, 44: 2268-2282. PMID: 40234722, DOI: 10.1038/s41388-025-03388-y.Peer-Reviewed Original ResearchConceptsLung metastasesTumor microenvironmentBreast cancerImaging Mass CytometryHLA-DR+Primary BCTME componentsEndothelial cellsTumour microenvironment of BCEpithelial cellsPaired lung metastasesExhausted T cellsTriple-negative subtypeMultiplex immunofluorescence analysisPrimary breast cancerAnti-angiogenic therapyDevelopment of therapeutic optionsFormalin-fixed paraffin-embedded (FFPEParaffin-embedded (FFPELung-specific metastasisOligo-metastasisMetastatic tumorsSurgical specimensMultiplex immunofluorescenceT cellsCas12a-knock-in mice for multiplexed genome editing, disease modelling and immune-cell engineering
Tang K, Zhou L, Tian X, Fang S, Vandenbulcke E, Du A, Shen J, Cao H, Zhou J, Chen K, Kim H, Luo Z, Xin S, Lin S, Park D, Yang L, Zhang Y, Suzuki K, Majety M, Ling X, Lam S, Chow R, Ren P, Tao B, Li K, Codina A, Dai X, Shang X, Bai S, Nottoli T, Levchenko A, Booth C, Liu C, Fan R, Dong M, Zhou X, Chen S. Cas12a-knock-in mice for multiplexed genome editing, disease modelling and immune-cell engineering. Nature Biomedical Engineering 2025, 9: 1290-1308. PMID: 40114032, PMCID: PMC12360953, DOI: 10.1038/s41551-025-01371-2.Peer-Reviewed Original ResearchKnock-In MiceBone marrow-derived dendritic cellsCD8+ T cellsNon-viral delivery vehiclesAdeno-associated virusDisease modelsCD4+Dendritic cellsC57BL/6 backgroundT cellsConstitutive expressionB cellsLipid nanoparticlesEx vivoGenome editingMiceMultiplex genome engineeringROSA26 locusGene interaction networksMultiplex genome editingLiver tissueTargeted genome editingDiseaseDelivery vehiclesCRISPR RNAAuthor Correction: Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy
Zhang F, Chow R, He E, Dong C, Xin S, Mirza D, Feng Y, Tian X, Verma N, Majety M, Zhang Y, Wang G, Chen S. Author Correction: Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy. Nature Biotechnology 2025, 1-1. PMID: 39901026, DOI: 10.1038/s41587-025-02576-1.Peer-Reviewed Original ResearchMultiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy
Zhang F, Chow R, He E, Dong C, Xin S, Mirza D, Feng Y, Tian X, Verma N, Majety M, Zhang Y, Wang G, Chen S. Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy. Nature Biotechnology 2025, 1-14. PMID: 39820813, DOI: 10.1038/s41587-024-02535-2.Peer-Reviewed Original ResearchAdeno-associated virusTumor microenvironmentImmunosuppressive genesAntitumor efficacyCD8+ T cell infiltrationIn vivo antitumor efficacyCombinatorial cancer immunotherapyImmunosuppressive tumor microenvironmentSyngeneic tumor modelsT cell infiltrationTumor microenvironment remodelingMulti-agent combinationsMultiple tumor typesAntitumor immunityCombinatorial immunotherapyOptimal immunotherapyCancer immunotherapyGene alterationsTumor typesTumor modelReduced neutrophilLiver toxicityShRNA treatmentWhole-transcriptome profilingImmunotherapy
2024
Pan-Cancer Single-Cell and Spatial-Resolved Profiling Reveals the Immunosuppressive Role of APOE+ Macrophages in Immune Checkpoint Inhibitor Therapy.
Liu C, Xie J, Lin B, Tian W, Wu Y, Xin S, Hong L, Li X, Liu L, Jin Y, Tang H, Deng X, Zou Y, Zheng S, Fang W, Cheng J, Dai X, Bao X, Zhao P. Pan-Cancer Single-Cell and Spatial-Resolved Profiling Reveals the Immunosuppressive Role of APOE+ Macrophages in Immune Checkpoint Inhibitor Therapy. Adv Sci (Weinh) 2024, 11: e2401061. PMID: 38569519, DOI: 10.1002/advs.202401061.Peer-Reviewed Original ResearchFatty acid-binding protein 5 is a functional biomarker and indicator of ferroptosis in cerebral hypoxia
Peng H, Xin S, Pfeiffer S, Müller C, Merl-Pham J, Hauck S, Harter P, Spitzer D, Devraj K, Varynskyi B, Arzberger T, Momma S, Schick J. Fatty acid-binding protein 5 is a functional biomarker and indicator of ferroptosis in cerebral hypoxia. Cell Death & Disease 2024, 15: 286. PMID: 38653992, PMCID: PMC11039673, DOI: 10.1038/s41419-024-06681-y.Peer-Reviewed Original ResearchConceptsFatty acid binding protein 5Cell deathFunction biomarkersProtein 5Death in vitroPositive-feedback loopFerroptotic cell deathLipidomics assaysIndicators of ferroptosisClinical investigationFerroptosis sensitivityWidespread cell deathEctopic expressionMarker antigensReactive speciesCerebral hypoxiaDamaged neuronsProtein dynamicsDeath processCell surfaceHuman pathophysiologyPostmortem patientsIron accumulationInvolvement of lipidsNeurodegenerative diseasesA multiomics analysis-assisted deep learning model identifies a macrophage-oriented module as a potential therapeutic target in colorectal cancer.
Bao X, Li Q, Chen D, Dai X, Liu C, Tian W, Zhang H, Jin Y, Wang Y, Cheng J, Lai C, Ye C, Xin S, Li X, Su G, Ding Y, Xiong Y, Xie J, Tano V, Wang Y, Fu W, Deng S, Fang W, Sheng J, Ruan J, Zhao P. A multiomics analysis-assisted deep learning model identifies a macrophage-oriented module as a potential therapeutic target in colorectal cancer. Cell Rep Med 2024, 5: 101399. PMID: 38307032, DOI: 10.1016/j.xcrm.2024.101399.Peer-Reviewed Original ResearchGenome scale CRISPR screens identify actin capping proteins as key modulators of therapeutic responses to radiation and immunotherapy.
Verma N, Renauer PA, Dong C, Xin S, Lin Q, Zhang F, Glazer PM, Chen S. Genome scale CRISPR screens identify actin capping proteins as key modulators of therapeutic responses to radiation and immunotherapy. BioRxiv 2024 PMID: 38293095, DOI: 10.1101/2024.01.14.575614.Peer-Reviewed Original Research
2023
An immunometabolism subtyping system identifies S100A9(+) macrophage as an immune therapeutic target in colorectal cancer based on multiomics analysis.
Bao X, Wang D, Dai X, Liu C, Zhang H, Jin Y, Tong Z, Li B, Tong C, Xin S, Li X, Wang Y, Liu L, Zhu X, Fu Q, Zheng Y, Deng J, Tian W, Guo T, Zhao P, Chen W, Fang W. An immunometabolism subtyping system identifies S100A9(+) macrophage as an immune therapeutic target in colorectal cancer based on multiomics analysis. Cell Rep Med 2023, 4: 100987. PMID: 36990096, DOI: 10.1016/j.xcrm.2023.100987.Peer-Reviewed Original Research
Get In Touch
Contacts
Email